Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
NCT06624371Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Mar 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atovaquone in glioma, diffuse midline glioma (DMG), diffuse intrinsic pontine glioma (DIPG) and 1 more (2 arms), sponsored by Emory University. Primary endpoint: Drug Limiting Toxicities at 10 weeks. Started Mar 2025; status: recruiting.
02
Drugs
atovaquone
03
Conditions
gliomadiffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)medulloblastoma
Beyond the preview
Go deeper on NCT06624371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624371.